Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1136-1144

  Park, Yongjung ^a   Kim, Yoonjung ^a   Lee, Eun Young ^a   Lee, Jong Han ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

biomarker; CA125; human epididymis protein 4 (HE4); ovarian cancer

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; AUTOMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; GYNECOLOGIC DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; PREGNANT WOMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOMATION; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEINS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 83655186047     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26129     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Curtin JP,. Management of the adnexal mass. Gynecol Oncol 1994; 55: S42-6.
3. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55: S4-14.
4. Schink JC,. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 1999; 26: 2-7. (Pubitemid 29093792)
5. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL,. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98: 172-80. (Pubitemid 43205479)
6. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C,. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006; 16 (Suppl 1): 11-7.
7. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL,. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002; 84: 36-42. (Pubitemid 34056463)
8. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC, Jr., Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-77. (Pubitemid 41502830)
9. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, Romagnolo C, Federghini M, Zucca S, Trio D, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994; 54: 117-23. (Pubitemid 24256456)
10. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T,. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008; 18: 414-20. (Pubitemid 351668303)
11. Bast RC, Jr., Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21: 200s-5s.
12. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP,. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003; 63: 2223-7. (Pubitemid 36538630)
13. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC,. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-9. (Pubitemid 34289219)
14. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ,. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993; 329: 1539-42. (Pubitemid 23332439)
15. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, Fioretti P,. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992; 44: 147-54.
16. Hellstrom I, Hellstrom KE,. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 2008; 622: 15-21.
17. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L,. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999; 238: 375-85. (Pubitemid 29446174)
18. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE,. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-700. (Pubitemid 36793054)
19. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL,. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-9. (Pubitemid 40490123)
20. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC, Jr., The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402-8. (Pubitemid 351174295)
21. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ,. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228 e1-6.
22. Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, Hellstrom KE,. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010; 296: 43-8.
23. Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N,. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res 2008; 14: 2647-55.
24. Halila H, Stenman UH, Seppala M,. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327-9. (Pubitemid 16136749)
25. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setala M, Harkki P, Jalkanen J, Fraser J, Makinen J, Auranen A, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315-9.
26. Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW,. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2480-7.
27. Bon GG, Kenemans P, Verstraeten R, van Kamp GJ, Hilgers J,. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 1996; 174: 107-14. (Pubitemid 26037697)
28. Malkasian GD, Jr., Knapp RC, Lavin PT, Zurawski VR, Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Jr, Ritts RE,. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341-6.
29. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N,. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006; 12: 2117-24.
30. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW,. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18: 1365-72.
31. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S, Franchi M, Guidi GC,. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009; 23: 331-5.
32. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
33. Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, Reale MG, Frati L, Midulla C,. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010; 31: 411-5.